A clinical formulation indicated for Oncology Support. Mechanism promotes the limitation of specific protein activity to restrict the proliferation of malignant cells.
Indicated to manage specific cancer types by addressing abnormal protein signaling to support long-term remission and alleviate disease progression in leukemia and GIST patients.
Mechanism of Action
Imatinib works by blocking a specific abnormal enzyme (BCR-ABL) that causes certain white blood cells to grow out of control. It targets this 'on switch' specifically, leaving healthy cells mostly unharmed.
Route of Administration
Oral
Onset Time
Steady state in 1 week
Duration
24 hours
Contraindications
Severe hypersensitivity to imatinib, Pregnancy
Severe Adverse Events
Severe liver injury, Congestive heart failure, Severe fluid retention in lungs, Bone marrow suppression, Gastrointestinal hemorrhage
Common Side Effects
Nausea, Muscle cramps, Skin rash
Uncommon Side Effects
Fluid retention (Edema), Diarrhea, Fatigue, Vomiting, Bone pain, Abdominal pain
Drug Interactions
Warfarin, Ketoconazole, Rifampin, Dexamethasone, Acetaminophen, St. John's Wort
Pregnancy Safety Warnings
Contraindicated; can cause severe fetal harm or death.
Age Restrictions
Approved for use in children for specific leukemia types.
Information for Gleevec is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
